Professional Media briefs

Elsevier is taking over publication of the Journal of Molecular Diagnostics, the journal of the Association for Molecular Pathology and the American Society for Investigative Pathology. The journal covers studies in oncology, infectious disease, inherited disease or predisposition to disease as well as advances in molecular diagnosis and application of diagnostic methodologies in clinical trials.

UBM Medica has acquired OBGYN.net from MediSpecialty.com. The women's health website, aimed at both patients and professionals, boasts a registered population of about 140,000 users and attracts more than 500,000 unique visitors a month with archived, searchable online forums, some going back more than ten years and comprising around a million posts all told. The site launched in 1996. UBM Medica sites include PsychiatricTimes.com, CancerNetwork.com and SearchMedica.com.

Wiley-Blackwell announced a publishing partnership with The Royal College of Speech and Language Therapists, the professional body for speech and language therapists in the UK. The publisher will produce the society's International Journal of Language and Communication Disorders beginning in 2011. The RCSLT boasts 14,000 members.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.